Replies to post #292841 on Amarin Corp Plc (AMRN)

[HinduKush]

sts
Generics and Du rely on a rather convoluted explanationthat uses a likely statistical misinterpretation of actual data in the paper by Hayashi et al to argue/justify the supposition that a single patient must have existed with TG>500mg/dl exposed to EPA 1800mg/day (28 pts with familial combined hyperlipidemias over 8 weeks) that had a TG lowering with no LDL elevation. Therefore, so the logic goes, this was obvious evidence that a POSA would have assumed already that EPA lowers TG>500mg/dl in an LDL neutral fashion. It is a scientific joke and an incredible contrived theory that Heineke and the generics sold to Du (much like all the othe shite she bought). As I pointed n two prior posts, in fact the graphs form the paper (that I reproduce below) that plotted ALL 28 patients data points do not extend the x-axis TG values beyond 350mg/dl. (This trial was looking at clotting parameters not aimed at lipid evaluations per se).
https://investorshub.advfn.com/uimage/uploads/2020/8/26/yuwnydu_generic_HAYASHI_ANALYSIS.png
https://investorshub.advfn.com/uimage/uploads/2020/8/26/obguzthe_hayashi_hypothesis.png

Here is the staistical gerrymandering that Du bought into..